Health Insurance
(Pharmaceutical Benefit) (General Provisions) (No. 2)
(Amendment No. 14) (Jersey) Order 2017
Made 6th October 2017
Coming into force 13th
October 2017
THE MINISTER FOR SOCIAL SECURITY, in pursuance of Articles 15, 17 and 36
of the Health Insurance (Jersey) Law 1967[1], orders as follows –
1 Health Insurance (Pharmaceutical Benefit)
(General Provisions) (No. 2) (Jersey) Order 2002 amended
In the Health Insurance (Pharmaceutical Benefit) (General
Provisions) (No. 2) (Jersey) Order 2002[2] –
(a) for
Article 9(5) there shall be substituted the following
paragraph –
“(5) The circumstances referred to
in paragraph (4) are where an approved supplier supplies by way of
pharmaceutical benefit a substance or product in accordance with a prescription
signed by an approved medical practitioner that specifies that it is to be
supplied in instalments at stipulated intervals or on given dates and, at the
time of supply, the substance or product is specified in Part 1, 2 or 3 of
Schedule 2 to the Misuse of Drugs (Jersey) Law 1978[3].”;
(b) for
Schedule 4 there shall be substituted the following Schedule –
|
Name of drug and form
|
|
|
|
|
|
A. Anticonvulsants
|
|
|
|
|
|
Acetazolamide
|
Tablets
250 mg
|
|
|
|
|
Carbamazepine
|
Tablets
100 mg; 200 mg; 400 mg
|
|
|
Tablets
M.R. 200 mg; 400 mg
|
|
|
Oral
liquid 100 mg per 5 ml
|
|
|
|
|
Clobazam
|
Tablets
10 mg
|
|
|
|
|
Clonazepam
|
Tablets
0.5 mg; 2 mg
|
|
|
|
|
Ethosuximide
|
Capsules
250 mg
|
|
|
Oral
liquid 250 mg per 5 ml
|
|
|
|
|
Lamotrigine
|
Tablets
25 mg; 50 mg; 100 mg; 200 mg
|
|
|
Dispersible
Tablets 2 mg; 5 mg; 25 mg; 100 mg
|
|
|
|
|
Levetiracetam
|
Tablet
250 mg; 500 mg; 750 mg;
|
|
|
Oral
solution 500 mg/5 ml
|
|
|
|
|
Phenobarbitone
|
Tablets
15 mg; 30 mg; 60 mg
|
|
|
Oral
solution15 mg/5 ml
|
|
|
|
|
Phenytoin
|
Capsules
25 mg; 50 mg; 100 mg; 300 mg
|
|
|
Infatabs
50 mg
|
|
|
Suspension
30 mg per 5 ml
|
|
|
|
|
Primidone
|
Tablets
250 mg
|
|
|
|
|
Sodium
Valproate
|
Syrup 200
mg per 5 ml;
|
|
|
Tablets
enteric coated 200 mg; 500 mg
|
|
|
Tablets
and Crushable 100 mg
|
|
|
Tablets
M.R. 200 mg; 300 mg; 500 mg
|
|
|
Sugar
free liquid 200 mg/5 ml
|
|
|
Capsules
M.R. 150 mg; 300 mg
|
|
|
Granules
500 mg/sachet, 1 g/sachet
|
|
|
|
|
Topiramate
|
Tablets
25 mg; 50 mg; 100 mg; 200 mg
|
|
|
Capsules
50 mg
|
|
|
Sprinkle
capsules 15 mg; 25 mg; 50 mg
|
|
|
|
B. Preparations for the management of diabetes
|
|
|
|
|
Acarbose
|
Tablets
50 mg; 100 mg
|
|
|
|
|
Canagliflozin
|
Tablets
100 mg; 300 mg
|
|
|
|
|
Clinitest
|
Tablets
|
|
|
|
|
Dapagliflozin
|
Tablets
5 mg; 10 mg
|
|
|
|
|
Empagliflozin
|
Tablets
10 mg; 25 mg
|
|
|
|
|
Exenatide
|
Injection
250 mcg/ml; 2 mg
|
|
|
|
|
Glibenclamide
|
Tablets
2.5 mg; 5 mg
|
|
|
|
|
Gliclazide
|
Tablets
80 mg
|
|
|
|
|
Insulin
preparations
|
All
insulins
|
|
|
|
|
Linagliptin
|
Tablets
5 mg
|
|
|
|
|
Liraglutide
|
Injection
6 mg/ml
|
|
|
|
|
Liraglutide/degludec
|
Injection
3.6 mg/100 IU
|
|
|
|
|
Metformin
|
Tablets
500 mg; 850 mg
|
|
|
Tablets
M.R. 500 mg; 750 mg; 1g
|
|
|
Oral
powder 500 mg/sachet; 1 g/sachet
|
|
|
|
|
Metformin/canagliflozin
|
Tablets
850 mg/50 mg; 1 g/50 mg
|
|
|
|
|
Metformin/dapagliflozin
|
Tablets
850 mg/5 mg/1g/5 mg
|
|
|
|
|
Metformin/linagliptin
|
Tablets
850 mg/2.5 mg; 1 g/2.5 mg
|
|
|
|
|
Metformin/pioglitazone
|
Tablets
850 mg/15 mg
|
|
|
|
|
Metformin/empagliflozin
|
Tablets
1g/5 mg, 1g/12.5 mg; 85 0mg/5 mg; 850 mg/12.5 mg
|
|
|
|
|
Pioglitazone
|
Tablets
15 mg; 30 mg; 45 mg
|
|
|
|
|
Saxagliptin
|
Tablets
2.5 mg; 5 mg
|
|
|
|
|
Sitagliptin
|
Tablets
25 mg; 50 mg; 100 mg
|
|
|
|
|
Sitagliptin/Metformin
|
Tablets
50 mg/1000 mg
|
|
|
|
|
Tolbutamide
|
Tablets
500 mg
|
|
|
|
|
Vildagliptin
|
Tablets
50 mg
|
|
|
|
|
Vildagliptin/Metformin
|
Tablets
50 mg/850 mg; 50 mg/1000 mg
|
|
|
|
C. Thyroid and antithyroid drugs
|
|
|
|
|
Carbimazole
|
Tablets
5 mg; 20 mg
|
|
|
|
|
Liothyronine
Sodium
|
Tablets 20
mcg
|
|
|
|
|
Levothyroxine
Sodium
|
Tablets
25 mcg; 50 mcg; 75 mcg; 100 mcg
|
|
Oral or transdermal
medicine used for contraception and containing any of the
following –
|
|
Co-cyprindiol
desogestrel
dienogest
drospirenone
estradiol hemihydrate
estradiol valerate
ethinylestradiol
gestodene
levonorgestel
mestranol
nomegestrol
norelgestromin
norgestimate
norethisterone
|
|
Oral, vaginal or
transdermal medicines containing the following female sex hormones when used
as hormone replacement therapy –
|
|
Conjugated oestrogens
Estradiol
Ethinylestradiol
Tibolone”.
|
2 Citation
and commencement
This Order may be cited as the Health Insurance (Pharmaceutical
Benefit) (General Provisions) (No. 2) (Amendment No. 14) (Jersey)
Order 2017 and shall come into force 7 days after it is made.
DEPUTY S.J. PINEL OF ST. CLEMENT
Minister for Social Security